Cybin Inc
Company Profile
Business description
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.
Contact
100 King Street West
Suite 5600
TorontoONM5X 1C9
CANT: +1 908 764-8385
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2026
Employees
50
Stocks News & Analysis
stocks
Picking dividend shares in 2026? Here’s where to look
stocks
Ahead of earnings, is Nvidia a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,686.30 | 8.30 | -0.10% |
| CAC 40 | 7,981.71 | 0.64 | 0.01% |
| DAX 40 | 23,216.60 | 62.25 | -0.27% |
| Dow JONES (US) | 45,752.26 | 386.51 | -0.84% |
| FTSE 100 | 9,522.09 | 5.56 | -0.06% |
| HKSE | 25,220.02 | 615.55 | -2.38% |
| NASDAQ | 22,078.05 | 486.18 | -2.15% |
| Nikkei 225 | 48,625.88 | 1,198.06 | -2.40% |
| NZX 50 Index | 13,419.40 | 20.00 | -0.15% |
| S&P 500 | 6,538.76 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,416.50 | 0.00 | 0.00% |
| SSE Composite Index | 3,834.89 | 96.16 | -2.45% |